Farzan brings more than two decades' leadership experience with a strong track record in fundraising and IPOs THOUSAND OAKS, Calif. , July 22, 2024 /PRNewswire/ -- Latigo Biotherapeutics Inc. ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, today announced the appointment of Nima Farzan , MBA, as chief executive officer (CEO).
Mr. Farzan brings a strong track record of more than two decades of leadership experience in the biopharmaceutical industry. He replaces Desmond Padhi , Pharm.
D., operating partner at Westlake Village BioPartners, who has been serving as Latigo's interim CEO. "The addition of Nima represents a pivotal moment for Latigo," said Nancy Stagliano , Ph.
D., chair of Latigo's board of directors. "His extensive industry leadership and clinical development experience will propel us toward our goal of becoming a world leader in discovering and developing non-opioid pain medicines.
" "I am honored to lead Latigo Biotherapeutics at such a critical juncture," said Farzan. "With our cutting-edge approach to pain management, I am confident in our ability to drive significant advancements in the field and enhance patient care where new, safer options are needed." "Desmond's leadership has been vital during a transformative period for Latigo, setting a solid stage for our next chapter of growth," said Stagliano.
"The board extends heartfelt thanks to Desmond for his exemplary service as i.